Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial - Ray, KK; Troquay, RPT; Visseren, FLJ (Lancet Diabetes Endocrinol, 2023)
et al.